006620 — DongKoo Bio & Pharma Co Balance Sheet
0.000.00%
Last trade - 00:00
- KR₩159bn
- KR₩205bn
- KR₩216bn
- 49
- 62
- 24
- 39
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 32,666 | 29,507 | 31,956 | 34,785 | 21,457 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 20,681 | 17,592 | 16,408 | 19,403 | 22,449 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 71,901 | 72,353 | 73,832 | 87,417 | 88,365 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 38,489 | 40,377 | 40,051 | 39,681 | 50,483 |
Net Intangible Assets | |||||
Long Term Investments | |||||
Long Term Notes Receivable | |||||
Other Long Term Assets | |||||
Total Assets | 132,725 | 144,353 | 154,786 | 172,059 | 191,103 |
Accounts Payable | |||||
Payable / Accrued | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 38,345 | 40,508 | 50,022 | 66,044 | 73,318 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Deferred Income Tax | |||||
Minority Interest | |||||
Total Other Liabilities | |||||
Total Funded Status | |||||
Total Liabilities | 47,073 | 49,701 | 54,662 | 69,953 | 80,703 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Treasury Stock | |||||
ESOP Debt Guarantee | |||||
Unrealized Gain / Loss | |||||
Other Equity | |||||
Total Equity | 85,652 | 94,653 | 100,124 | 102,106 | 110,400 |
Total Liabilities & Shareholders' Equity | 132,725 | 144,353 | 154,786 | 172,059 | 191,103 |
Total Common Shares Outstanding |